#Ubix Therapeutics is proud to have participated in the #ASH 2023. Our team had the opportunity to learn about the latest developments in the field of hematology and engage with some of the brightest minds in the industry. Thank you to everyone who visited our posters. At Ubix, we are committed to staying at the forefront of innovation in oncology by developing targeted protein degraders. Stay tuned for more updates along our journey.